Tagrisso Approved in the US for Patients with Unresectable, Stage III EGFR-Mutated Lung Cancer

3 months ago

by David Miller

947 Views

Written by David Miller

Cambridge, UK –26 September 2024–AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!